Modulating the activity of the Src Homology 2 (SH2) — containing Inositol 5′-Phosphatase (SHIP) enzyme family with small molecule inhibitors provides a useful and unconventional method of influencing cell signaling in the PI3K pathway. The development of small molecules that selectively target one of the SHIP paralogs (SHIP1 or SHIP2) as well as inhibitors that simultaneously target both enzymes have provided promising data linking the phosphatase activity of the SHIP enzymes to disorders and disease states that are in dire need of new therapeutic targets. These include cancer, immunotherapy, diabetes, obesity, and Alzheimer's disease. In this mini-review, we will provide a brief overview of research in these areas that support targeting SHIP1, SHIP2 or both enzymes for therapeutic purposes.
Review Article| February 12 2020
Small molecule targeting of SHIP1 and SHIP2
William G. Kerr;
1Department of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, NY, U.S.A.
2Department of Chemistry, Syracuse University, Syracuse, NY, U.S.A.
3Department of Pediatrics, SUNY Upstate Medical University, Syracuse, NY, U.S.A.
Correspondence: William G. Kerr (email@example.com)
Search for other works by this author on:
- Views Icon Views
- Share Icon Share
- Cite Icon Cite
William G. Kerr, Chiara Pedicone, Shawn Dormann, Angela Pacherille, John D. Chisholm; Small molecule targeting of SHIP1 and SHIP2. Biochem Soc Trans 28 February 2020; 48 (1): 291–300. doi: https://doi.org/10.1042/BST20190775
Download citation file: